Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)

Olivares, J.M.; Rodriguez-Morales, A.; Diels, J.; Povey, M.; Jacobs, A.; Zhao, Z.; Lam, A.

doi:10.1016/j.eurpsy.2008.12.002

Cited by 141Schizophrenia research and treatmentPsychiatric care and mental health servicesMedication Adherence and Compliance

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)

Olivares, J.M., Rodriguez-Morales, A., Diels, J., Povey, M., Jacobs, A., Zhao, Z., Lam, A.·2009·European Psychiatry

DOI 10.1016/j.eurpsy.2008.12.002

Open this paper in CoChat — free account

Abstract

Background: The electronic Schizophrenia Treatment Adherence Registry (e-STAR) is a prospective, observational study of patients with schizophrenia designed to evaluate long-term treatment outcomes in routine clinical practice. Methods: Parameters were assessed at baseline and at 3 month intervals for 2 years in patients initiated on risperidone long-acting injection (RLAI) (n= 1345) or a new oral antipsychotic (AP) (n= 277; 35.7% and 36.5% on risperidone and olanzapine, respectively) in Spain. Hospitalization prior to therapy was assessed by a retrospective chart review. Results: At 24 months, treatment retention (81.8% for RLAI versus 63.4% for oral APs,p< 0.0001) and reduction in Clinical Global Impression Severity scores (−1.14 for RLAI versus −0.94 for APs,p= 0.0165) were significantly higher with RLAI. Compared to the pre-switch period, RLAI patients had greater reductions in the number (reduction of 0.37 stays per patient versus 0.2,p< 0.05) and days (18.74 versus 13.02,p< 0.01) of hospitalizations at 24 months than oral AP patients. Conclusions: This 2 year, prospective, observational study showed that, compared to oral antipsychotics, RLAI was associated with better treatment retention, greater improvement in clinical symptoms and functioning, and greater reduction in hospital stays and days in hospital in patients with schizophrenia. Improved treatment adherence, increased efficacy and reduced hospitalization with RLAI offer the opportunity of substantial therapeutic improvement in schizophrenia.

Integrity signals

Registry

Crossref · 10.1016/j.eurpsy.2008.12.002

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Patients on injectable medication were more likely to be adherent than patients taking drugs orally.
“The patients on injectable medication were more likely to be adherent than the patient taking drugs orally [46].”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [46]
Taking medication twice per day was a negative factor for medication adherence in two studies.
“In another two studies, taking medication twice per day was a negative factor for medication adherence [46, 49].”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [46]
Patients' or caregivers' perceived medication efficacy such as subjective relief of symptoms, patients' feel drugs have no effect on the illness, not helpful, being ineffective, and feeling of cured were side-effect-related factors associated with medication non-adherence.
“Likewise, patients’ or caregivers’ perceived medication efficacy such as subjective relief of symptoms, patients’ feel drugs have no effect on the illness, not helpful, being ineffective [36, 46, 50], and feeling of cured [51] were side-effect-related factors associated with medication non-adherence.”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [46]
Medication non-adherence was affected by the number of hospitalizations, irregular hospitalization and frequently discharge of patients, length of stay, lack of patients' satisfaction with health care services, and long distance to access the health service/recollect medications.
“Medication non-adherence was affected by the number of hospitalizations [28], irregular hospitalization and frequently discharge of patients, length of stay [42, 46], lack of patients’ satisfaction with health care services [44], and long distance to access the health service/recollect medications [50].”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [46]

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · see citing works
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982 · see citing works
Why we need observational studies to evaluate the effectiveness of health care
Black, N. (1996) · BMJ · doi:10.1136/bmj.312.7040.1215 · Cited by 1,598 · see citing works
Clinical Global Impression
Guy, W. L. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,441 · see citing works
Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia: A Comprehensive Review of Recent Literature
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 1× · see citing works
“A number of studies have associated low patient insight with poor medication compliance [19,20].”
Background
Handbook of Psychiatric Measures
Salzman, C. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1343 · Cited by 1,172 · see citing works
Handbook of Psychiatric Measures
Rush, A. J., First, M. B., & Blacker, D. (2000) · Medical Entomology and Zoology · Cited by 846 · see citing works
Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic
Kane, J. M., Eerdekens, M., Lindenmayer, J., Keith, S. J., Lesem, M. D., & Karcher, K. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.6.1125 · Cited by 489 · see citing works
Content and quality of 2000 controlled trials in schizophrenia over 50 years
Thornley, B., & Adams, C. E. (1998) · BMJ · doi:10.1136/bmj.317.7167.1181 · Cited by 362 · see citing works
Pharmacy Data Identify Poorly Adherent Patients With Schizophrenia at Increased Risk for Admission
Valenstein, M. M., Copeland, L. A., Blow, F. C., McCarthy, J. F., Zeber, J. E., Gillon, L., Bingham, C. R., & Stavenger, T. (2002) · Medical Care · doi:10.1097/00005650-200208000-00002 · Cited by 333 · see citing works
Guidelines for depot antipsychotic treatment in schizophrenia
Kane, J. M., Aguglia, E., Altamura, A. C., Gutiérrez, J. L., Brunello, N., Fleischhacker, W. W., Gaebel, W., Gerlach, J., Guelfi, J.-D., Kissling, W., et al. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00045-x · Cited by 331 · see citing works
Depot Antipsychotic Drugs
Davis, J. M., Metalon, L., Watanabe, M. D., & Blake, L. M. (1994) · Drugs · doi:10.2165/00003495-199447050-00004 · Cited by 295 · see citing works
Treatment of Schizophrenia With Long-Acting Injectable Risperidone
Fleischhacker, W. W., Eerdekens, M., Karcher, K., Remington, G. J., Llorca, P., Chrzanowski, W., Martin, S. D., & Gefvert, O. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1017 · Cited by 288 · see citing works
Systematic meta-review of depot antipsychotic drugs for people with schizophrenia
Adams, C. E., Fenton, M., Quraishi, S. N., & David, A. S. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.4.290 · Cited by 286 · see citing works
Poor Antipsychotic Adherence Among Patients With Schizophrenia: Medication and Patient Factors
Valenstein, M. M., Blow, F. C., Copeland, L. A., McCarthy, J. F., Zeber, J. E., Gillon, L., Bingham, C. R., & Stavenger, T. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007076 · Cited by 273 · see citing works
Economics and Schizophrenia: The Real Cost
Davies, L. M., & Drummond, M. (1994) · The British Journal of Psychiatry · doi:10.1192/s0007125000293161 · Cited by 216 · see citing works
Medication noncompliance in schizophrenia: codification and update.
Young, J. L., Zonana, H. V., & Shepler, L. (1986) · PubMed · Cited by 198 · see citing works
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets
Chue, P. S., Eerdekens, M., Augustyns, I., Lachaux, B., Molčan, P., Eriksson, L., Pretorius, H., & David, A. S. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.07.003 · Cited by 197 · see citing works
The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment
Watt, D. C., Katz, K. S., & Shepherd, M. A. (1983) · Psychological Medicine · doi:10.1017/s0033291700048091 · Cited by 186 · see citing works
Medication Adherence in Schizophrenia: Exploring Patients', Carers' and Professionals' Views
Kikkert, M. J., Schene, A. H., Koeter, M. W. J., Robson, D., Born, A., Helm, H., Nose, M., Goss, C., Thornicroft, G., & Gray, R. J. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl011 · Cited by 164 · see citing works
Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results
Haro, J. M., Suarez, D. L., Novick, D., Brown, J., Usall, J., & Naber, D. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.09.005 · Cited by 129 · see citing works
Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS®) and its relationship to sociodemographic, clinical and psychopathological variables
Acosta, F. J., Bosch, E., Sarmiento, G., Juanes, N., Caballero-Hidalgo, A., & Mayans, T. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.007 · Cited by 119 · see citing works
Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies
ller, H.-J. R. M., Llorca, P., Sacchetti, E., Martin, S. D., Medori, R., & Parellada, E. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200505000-00001 · Cited by 115 · see citing works
Selection Bias in Clinical Trials With Antipsychotics
Hofer, A., Hummer, M., Huber, R., Kurz, M., Walch, T., & Fleischhacker, W. W. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00019 · Cited by 112 · see citing works
A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia
Bhanji, N. H., Chouinard, G., & Margolese, H. C. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)00109-3 · Cited by 99 · see citing works
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics
Turner, M., Eerdekens, E., Jacko, M., & Eerdekens, M. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000133500.92025.20 · Cited by 81 · see citing works
Subject Selection Biases in Clinical Trials
Robinson, D. G., Woerner, M. G., Pollack, S. Z., & Lerner, G. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00009 · Cited by 78 · see citing works
Cost-Effectiveness Analysis of Switching Antipsychotic Medication to Long-Acting Injectable Risperidone in Patients with Schizophrenia
Olivares, J. M., Rodríguez-Martínez, A., Burón, J. A., Alonso‐Escolano, D., & Rodríguez-Morales, A. (2008) · Applied Health Economics and Health Policy · doi:10.2165/00148365-200806010-00004 · Cited by 64 · see citing works
Self-citation
Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome
Taylor, D. M., Young, C., & Patel, M. X. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006309 · Cited by 48 · see citing works
Hospitalization Rates in Patients During Long-Term Treatment With Long-Acting Risperidone Injection
Chue, P. S., Llorca, P., Duchesne, I., Leal, A., Rosillon, D., Montpied, H. G., & Ferrand, C. (2005) · Cited by 44 · see citing works
Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic
Chue, P. S. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2007.3.1.13 · Cited by 37 · see citing works
Long-acting risperidone in stable patients with schizoaffective disorder
Mohl, A., Westlye, K., Opjordsmoen, S., Lex, A., Schreiner, A., Benoît, M., Bräunig, P., & Medori, R. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056515 · Cited by 35 · see citing works
Long-acting risperidone injection
Love, R. C., & Conley, R. J. (2004) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/61.17.1792 · Cited by 29 · see citing works
Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval
Gharabawi, G. M., Gearhart, N. C., Lasser, R. A., Mahmoud, R. A., Zhu, Y., Mannaert, E., Naessens, I., Bossie, C. A., Kujawa, M., & Simpson, G. M. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-3 · Cited by 27 · see citing works
Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia
Beauclair, L., Chue, P. S., McCormick, J., Camacho, F., Lam, A., & Luong, D. (2007) · Journal of Medical Economics · doi:10.3111/13696990701646825 · Cited by 19 · see citing works
Self-citation
PMH9 TREATMENT RETENTION WITH RISPERIDONE LONG ACTING INJECTION (RLAI) IN EUROPEAN PATIENTS WITH SCHIZOPHRENIA: 12-MONTH INTERIM RESULTS FROM ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR)
Olivares, J., Peuskens, J., Pečeňák, J., Tuma, L., van Kooten, M., Eriksson, L., Povey, M., Lam, A., & Zhao, Z. Y. (2007) · Value in Health · doi:10.1016/s1098-3015(10)65059-0 · Cited by 2 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis
Semahegn, A., Torpey, K., Manu, A., Assefa, N., Tesfaye, G., & Ankomah, A. (2020) · Systematic Reviews · doi:10.1186/s13643-020-1274-3 · Cited by 555 · see citing works
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 418 · see citing works
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies
Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00039-0 · Cited by 369 · see citing works
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297 · see citing works
Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review
Olivares, J. M., Sermon, J., Hemels, M., & Schreiner, A. (2013) · Annals of General Psychiatry · doi:10.1186/1744-859x-12-32 · Cited by 270 · see citing works
Self-citation
Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder
Quiroz, J. A., Yatham, L. N., Palumbo, J. M., Karcher, K., Kushner, S., & Kusumakar, V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.015 · Cited by 200 · see citing works
Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia
Kaplan, G., Casoy, J., & Zummo, J. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s53795 · Cited by 201 · see citing works
Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies
Kishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., & Correll, C. U. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx090 · Cited by 186 · see citing works
Efficacy and Effectiveness of Depot Versus Oral Antipsychotics in Schizophrenia
Kirson, N. Y., Weiden, P. J., Yermakov, S., Huang, W., Samuelson, T., Offord, S. J., Greenberg, P. E., & Wong, B. J. O. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08167 · Cited by 177 · see citing works
Prediction of disability in schizophrenia: Symptoms, cognition, and self-assessment
Harvey, P. D., Strassnig, M., & Silberstein, J. (2019) · Journal of Experimental Psychopathology · doi:10.1177/2043808719865693 · Cited by 141 · see citing works
A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder
Vieta, E., Montgomery, S., Sulaiman, A. H., Cordoba, R., Huberlant, B., Martinez, L., & Schreiner, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.03.004 · Cited by 130 · see citing works
Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial
Gäebel, W., Schreiner, A., Bergmans, P., de Arce, R., Rouillon, F., Cordes, J., Eriksson, L., & Smeraldi, E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.111 · Cited by 111 · see citing works
Long acting injection versus oral risperidone in first-episode schizophrenia: Differential impact on white matter myelination trajectory
Bartzokis, G., Lu, P. H., Amar, C. P., Raven, E. P., DeTore, N. R., Altshuler, L. L., Mintz, J., Ventura, J., Casaus, L. R., Luo, J. S., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.06.029 · Cited by 95 · see citing works
Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective
Nicholl, D., Akhras, K. S., Diels, J., & Schadrack, J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003658956 · Cited by 83 · see citing works
Self-citation
Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia
Bartzokis, G., Lu, P. H., Raven, E. P., Amar, C. P., DeTore, N. R., Couvrette, A., Mintz, J., Ventura, J., Casaus, L. R., Luo, J. S., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.036 · Cited by 81 · see citing works
Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis
Lafeuille, M., Laliberté-Auger, F., Lefèbvre, P., Frois, C., Fastenau, J. M., & Duh, M. S. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-221 · Cited by 76 · see citing works
Longitudinal changes of insight in first episode psychosis and its relation to clinical symptoms, treatment adherence and global functioning: One-year follow-up from the Eiffel study
Segarra, R., Ojeda, N., Peña, J., García‐Ormaza, J., Rodríguez-Morales, A., Ruiz, I., Hidalgo, R., Burón, J. A., Eguíluz, J. I., & Gutiérrez, M. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2010.06.003 · Cited by 64 · see citing works
Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective
Rauch, A.-S., & Fleischhacker, W. W. (2013) · CNS Drugs · doi:10.1007/s40263-013-0083-9 · Cited by 64 · see citing works
Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries
Peuskens, J., Olivares, J. M., Pečeňák, J., Tuma, I. S. M., de Weg, H. B., Eriksson, L., Resseler, S., Akhras, K. S., Jacobs, A., & on behalf of the e-STAR study group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903488670 · Cited by 64 · see citing works
Self-citation
Stress and burden faced by family caregivers of people with schizophrenia and early psychosis in Hong Kong
Wan, K., & Wong, M. M. C. (2019) · Internal Medicine Journal · doi:10.1111/imj.14166 · Cited by 64 · see citing works
Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry
Olivares, J. M., Peuskens, J., Pečeňák, J., Resseler, S., Jacobs, A., Akhras, K. S., & on behalf of the e-STAR study group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903149306 · Cited by 62 · see citing works
Self-citation
Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment
Lambert, M., Marinis, T. D., Pfeil, J., Naber, D., & Schreiner, A. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.09.001 · Cited by 62 · see citing works
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
Coppola, D., Liu, Y., Gopal, S., Remmerie, B., Samtani, M. N., Hough, D. W., Nuamah, I., Sulaiman, A., & Pandina, G. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-26 · Cited by 61 · see citing works
Factors associated with relapse in patients with schizophrenia
San, L., Bernardo, M., de la Cámara, A. G., & Peña, M. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.687452 · Cited by 60 · see citing works
Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
Zhang, F., Si, T., Chiou, C., Harris, A. W. F., Kim, C. Y., Jahagirdar, P., & Ascher, S. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s77778 · Cited by 56 · see citing works
Long-Acting Injectable Antipsychotics: Evidence of Effectiveness and Use
Manchanda, R., Chue, P. S., MALLA, A. K., Tibbo, P. G., Roy, M., Williams, R. L., Iyer, S. N., Lutgens, D., & Banks, N. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/088740341305805s02 · Cited by 55 · see citing works
Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia
Lafeuille, M., Dean, J., Carter, V. A., Duh, M. S., Fastenau, J. M., Dirani, R. D., & Lefèbvre, P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.915211 · Cited by 52 · see citing works
Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
Druais, S., Doutriaux, A., Cognet, M., Godet, A., Lançon, C., Lévy, P., Samalin, L., & Guillon, P. (2016) · PharmacoEconomics · doi:10.1007/s40273-015-0348-x · Cited by 51 · see citing works
Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate
Simpson, S. M., Widanapathirana, L., Su, J. T., Sung, S., Watrous, D., Qiu, J., Pearson, E. K., Evanoff, A., Karunakaran, D., Chacon, J. E., et al. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-2777-2 · Cited by 45 · see citing works
Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics &ndash; expert consensus survey part 1
Sajatovic, M., Ross, R., Legacy, S. N., Correll, C. U., Kane, J. M., DiBiasi, F., Fitzgerald, H., & Byerly, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167394 · Cited by 44 · see citing works
Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics
Lafeuille, M., Grittner, A. M., Fortier, J., Muser, E., Fasteneau, J., Duh, M. S., & Lefèbvre, P. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140219 · Cited by 44 · see citing works
Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies
Fagiolini, A. M., Rocca, P., Giorgi, S. D., Spina, E., Amodeo, G., & Amore, M. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.11.044 · Cited by 44 · see citing works
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices
Shafrin, J. T., Kim, J., Cohen, J. T., Garrison, L. P., Goldman, D. P., Doshi, J. A., Krieger, J., Lakdawalla, D. N., Neumann, P. J., Phelps, C. E., et al. (2024) · Forum for Health Economics & Policy · doi:10.1515/fhep-2024-0014 · Cited by 40 · see citing works
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Patel, M. X., Bent‐Ennakhil, N., Sapin, C., di Nicola, S., Loze, J.-Y., Nylander, A.-G., & Heres, S. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02530-2 · Cited by 40 · see citing works
A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
Schreiner, A., Bergmans, P., Cherubin, P., Keim, S., Rancāns, E., Bez, Y., Parellada, E., Carpiniello, B., Vidailhet, P., & Hargarter, L. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.014 · Cited by 42 · see citing works
A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal
Suzuki, T. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1115479 · Cited by 40 · see citing works
Accuracy of Clinician Assessments of Medication Status in the Emergency Setting
Lopez, L. V., Shaikh, A., Merson, J., Greenberg, J., Suckow, R. F., & Kane, J. M. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000697 · Cited by 38 · see citing works
Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden
Mehnert, A., Nicholl, D., Pudas, H., Martin, M., & McGuire, A. J. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.681531 · Cited by 34 · see citing works
Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients
San, L., Bernardo, M., de la Cámara, A. G., Martínez, P., González, B., & Peña, M. (2012) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2012.667150 · Cited by 34 · see citing works
Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs
Bossie, C. A., Alphs, L. D., & Correll, C. U. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000082 · Cited by 33 · see citing works
A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization rates
Bressington, D. T., Stock, J., Hulbert, S., & MacInnes, D. L. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000077 · Cited by 33 · see citing works
Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
Zeidler, J., Mahlich, J., Greiner, W., & Heres, S. (2013) · Applied Health Economics and Health Policy · doi:10.1007/s40258-013-0050-0 · Cited by 32 · see citing works
Release mechanisms of tacrolimus-loaded PLGA and PLA microspheres and immunosuppressive effects of the microspheres in a rat heart transplantation model
Kojima, R., Yoshida, T., Tasaki, H., Umejima, H., Maeda, M., Higashi, Y., Watanabe, S., & Oku, N. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.07.004 · Cited by 32 · see citing works
Single- and Multiple-Dose Pharmacokinetic, Safety, and Tolerability Profiles of Olanzapine Long-Acting Injection: An Open-Label, Multicenter, Nonrandomized Study in Patients With Schizophrenia
Mitchell, M., Kothare, P., Bergstrom, R., Zhao, F., Jen, K. Y., Walker, D., Johnson, J., & McDonnell, D. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.023 · Cited by 31 · see citing works
Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results
Macfadden, W., DeSouza, C., Crivera, C., Kozma, C. M., Dirani, R. D., Mao, L., & Rodriguez, S. C. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-167 · Cited by 31 · see citing works
Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
Rocca, P., Montemagni, C., & Frieri, T. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s88632 · Cited by 31 · see citing works
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review
Cañas, F., & Möller, H. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.506712 · Cited by 30 · see citing works
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
Gopal, S., Berwaerts, J., Nuamah, I. F., Akhras, Coppola, Daly, Hough, D., & Palumbo, J. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s17177 · Cited by 29 · see citing works
Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System
Fuller, M. A., Shermock, K. M., Russo, P., Secic, M., Dirani, R. D., Vallow, S., & Flanders, S. C. (2009) · Journal of Medical Economics · doi:10.3111/13696990903303902 · Cited by 29 · see citing works
Effectiveness of long-acting injectable antipsychotics: a clinical perspective
Castillo, E. G., & Stroup, T. S. (2015) · Evidence Based Mental Health · doi:10.1136/eb-2015-102086 · Cited by 28 · see citing works
Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden
Einarson, T. R., Vicente, C., Zilbershtein, R., Piwko, C., Bø, C. N., Pudas, H., Jensen, R., & Hemels, M. E. H. (2013) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2013.852243 · Cited by 28 · see citing works
Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia
Panish, J. M., Karve, S. J., Candrilli, S. D., & Dirani, R. D. (2013) · Journal of Pharmaceutical Health Services Research · doi:10.1111/jphs.12004 · Cited by 28 · see citing works
Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study
Brnabic, A. J. M., Kelin, K., Ascher‐Svanum, H., Montgomery, W. S., KADZIOLA, Z. A., & Karagianis, J. L. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02743.x · Cited by 28 · see citing works
Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data
Mahlich, J., Kuwabara, H., & Yoshimichi, S. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s81677 · Cited by 28 · see citing works
Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment
Pesa, J. A., Doshi, D., Wang, L., Yüce, H., & Baser, O. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1278202 · Cited by 28 · see citing works
Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
Einarson, T. R., Geitona, M., Chaidemenos, A., Karpouza, V., Mougiakos, T., Paterakis, P., Ploumpidis, D., Potamitis-Komis, D., Zilbershtein, R., Vicente, C., et al. (2012) · Annals of General Psychiatry · doi:10.1186/1744-859x-11-18 · Cited by 27 · see citing works
Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting
Joshi, K., Lafeuille, M., Brown, B., Wynant, W., Émond, B., Lefèbvre, P., & Tandon, N. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1359516 · Cited by 27 · see citing works
Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia
Olivares, J. M., Pinal, B., & Cinos, C. (2011) · Neuropsychiatry · doi:10.2217/npy.11.24 · Cited by 26 · see citing works
Self-citation
Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia
Dammerman, R. S., Kim, S., Adera, M., & Schwarz, A. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.428 · Cited by 26 · see citing works
Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands
Einarson, T., Bereza, B. G., Tedouri, F., Impe, K. V., Denee, T. R., & Dries, P. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1363050 · Cited by 23 · see citing works
Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study
Llorca, P., Bobes, J., Fleischhacker, W. W., Heres, S., Moore, N. D., Bent‐Ennakhil, N., Sapin, C., Loze, J.-Y., Nylander, A., & Patel, M. X. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.04.004 · Cited by 25 · see citing works
Reasons associated with treatment non-adherence in schizophrenia in a Pakistan cohort
Ahmad, I., Khalily, M. T., & Hallahan, B. P. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.07.024 · Cited by 25 · see citing works
Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
Gopal, S., Liu, Alphs, L. D., Savitz, Nuamah, I. F., & Hough, D. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s49944 · Cited by 24 · see citing works
Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland
Einarson, T. R., Pudas, H., Goswami, P., Impe, K. V., & Bereza, B. G. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1100115 · Cited by 24 · see citing works
Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting Injectable
de la rosa, F. G., Schreiner, A., Thomas, P., & Sherif, T. (2012) · Clinical Drug Investigation · doi:10.2165/11599080-000000000-00000 · Cited by 23 · see citing works
Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study
de la Gándara, J., San, L., Rubio, G., Rodríguez-Morales, A., Borrajo, R. H., & Burón, J. A. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.96 · Cited by 23 · see citing works
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal
Einarson, T. R., Maia-Lopes, S., Goswami, P., Bereza, B. G., & Impe, K. V. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1184156 · Cited by 22 · see citing works
The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization
Nasrallah, H. A., Harvey, P. D., Casey, D. E., Csoboth, C. T., Hudson, J. I., Julian, L. J., Lentz, E. L., Nuechterlein, K. H., Perkins, D. O., Kotowsky, N., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.04.031 · Cited by 21 · see citing works
Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study
Mahlich, J., Olbrich, K., Wilk, A., Wimmer, A., & Wolff‐Menzler, C. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00900-y · Cited by 21 · see citing works
Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?
Niolu, C., Bianciardi, E., Lorenzo, G. D., Marchetta, C., Barone, Y., Sterbini, N., Ribolsi, M., Reggiardo, G., & Siracusano, A. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315596897 · Cited by 20 · see citing works
Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study
Magliocco, F., de Filippis, R., Aloi, M., Staltari, F. A., Gaetano, R., Segura‐Garcìa, C., & Fazio, P. D. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1737134 · Cited by 20 · see citing works
Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS)
Schreiner, A., Svensson, A. E., Wapenaar, R., Chérubin, P., Princet, P., Serazetdinova, L., & Zink, M. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.902990 · Cited by 20 · see citing works
Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate
Joshi, K., Pan, X., Wang, R., Yang, E., & Benson, C. J. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1219706 · Cited by 19 · see citing works
Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics
Voss, E. A., Ryan, P. B., Stang, P., Hough, D., & Alphs, L. D. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000068 · Cited by 19 · see citing works
Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
Mahlich, J., Masamichi, N., & Yoshimichi, S. (2015) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s85514 · Cited by 18 · see citing works
Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries
Sultana, J., Hurtado, I., Bejarano‐Quisoboni, D., Giorgianni, F., Huybrechts, K. F., Lu, Z., Patorno, E., Sanfélix‐Gimeno, G., Tari, D. U., & Trifirò, G. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02654-9 · Cited by 18 · see citing works
Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study
Schreiner, A., Caspi, A., Bergmans, P., Chérubin, P., Keim, S., Lara, E., Пінчук, І., Schuepbach, D., Suleman, S., & Hargarter, L. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4445-0 · Cited by 17 · see citing works
Influence of type of treatment on the well-being of Spanish patients with schizophrenia and their caregivers
Bravo‐Ortiz, M. F., Gutiérrez-Casares, J. R., Rodríguez-Morales, A., García, M. A. P., & Borrajo, R. H. (2011) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2011.608469 · Cited by 17 · see citing works
Nurses’ perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey
Emsley, R. A., Alptekın, K., Azorin, J., Cañas, F., Dubois, V., Gorwood, P. A. P. M., Haddad, P. M., Naber, D., Olivares, J. M., Papageorgiou, G., et al. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315612013 · Cited by 17 · see citing works
Self-citation
Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland
Einarson, T. R., Pudas, H., Zilbershtein, R., Jensen, R., Vicente, C., Piwko, C., & Hemels, M. E. H. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.823869 · Cited by 16 · see citing works
Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia–Pacific survey
Olivares, J. M., Thirunavukarasu, Kulkarni, J., Yan, Y., Zhang, & Zhang (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s49080 · Cited by 16 · see citing works
Self-citation
Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
Kamei, H. (2022) · Medicina · doi:10.3390/medicina58111584 · Cited by 15 · see citing works
Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
Apiquián, R., Córdoba, R., & Louzã, M. R. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s15911 · Cited by 15 · see citing works
Should full adherence be a necessary goal in schizophrenia? Full versus non-full adherence to antipsychotic treatment
Acosta, F. J., Ramallo‐Fariña, Y., & Siris, S. G. (2013) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2013.09.005 · Cited by 15 · see citing works
Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database
Lambert, T. J. R., Emmerson, B., Hustig, H., Resseler, S., Jacobs, A., & Butcher, B. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-25 · Cited by 15 · see citing works
Self-citation
Depot/Long Acting Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
Özgüven, H. D., & Kır, Y. (2021) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.27480 · Cited by 14 · see citing works
Psychiatrists’ perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa
Gorwood, P. A. P. M., Burns, T., Juckel, G., Rossi, A., San, L., Hargarter, L., Schreiner, A., & on behalf of the Europe, M. E. A. A. F. G. (2013) · Annals of General Psychiatry · doi:10.1186/1744-859x-12-8 · Cited by 14 · see citing works
Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic
Einarson, T. R., Zilbershtein, R., Skoupá, J., Veselá, Š., Garg, M., & Hemels, M. E. H. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.820193 · Cited by 13 · see citing works
The cost–effectiveness of risperidone long-acting injection in the treatment of schizophrenia
Chue, P. S., & Chue, J. (2012) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.12.23 · Cited by 12 · see citing works
Poor Adherence to Antipsychotic Medication in People with Schizophrenia: Diffusion, Consequences and Contributing Factors
Sacchetti, E., & Vita, A. (2013) · Springer eBooks · doi:10.1007/978-88-470-2679-7_1 · Cited by 11 · see citing works
Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia
Jukić, V., Jakovljević, M., Filipčić, I., Herceg, M., Silić, A., Tomljanović, T., Zilbershtein, R., Jensen, R., Hemels, M. E. H., & Einarson, T. R. (2013) · Value in Health Regional Issues · doi:10.1016/j.vhri.2013.06.008 · Cited by 12 · see citing works
Impact of long-acting injectable antipsychotics vs. oral medication on relapses of patients with psychosis and bipolar disorder
Vgontzas, A. N., Paschalidou, A., Simos, P. G., Anastasaki, M., Zografaki, A., Volikos, E., Koutra, K., & Basta, M. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115676 · Cited by 10 · see citing works
Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
Ascher‐Svanum, H., Montgomery, B., McDonnell, D., Coleman, & Feldman, P. D. (2012) · International Journal of General Medicine · doi:10.2147/ijgm.s29052 · Cited by 10 · see citing works
Financial impact of a pharmacist-managed clinic for long-acting injectable antipsychotics
Phan, S. V., & VandenBerg, A. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110647 · Cited by 10 · see citing works
Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
Kamei, H., Homma, Y., Takeuchi, I., Hajitsu, G., Tozawa, K., Hatano, M., Fukui, A., Hanya, M., Yamada, S., & Iwata, N. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.1.49 · Cited by 10 · see citing works
Association between Medication Adherence and Duration of Outpatient Treatment in Patients with Schizophrenia
Tarutani, S., Kikuyama, H., Ohta, M., Kanazawa, T., Okamura, T., & Yoneda, H. (2016) · Psychiatry Investigation · doi:10.4306/pi.2016.13.4.413 · Cited by 10 · see citing works
Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia
Alphs, L. D., Bossie, C. A., Fu, D., Ma, Y.-W., & Sliwa, J. K. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.909409 · Cited by 9 · see citing works
Guidance on the clinical understanding and use of long‐acting injectable antipsychotics in Schizophrenia: Hong Kong Consensus Statements
Wong, M. M. C., Chung, A. K. K., Yeung, T. M. H., Wong, D. T. W., Lee, C. K., Lai, C. L. E., Chan, G. F. Y., Mak, G. K. L., Wong, J. O. Y., Ng, R., et al. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13374 · Cited by 9 · see citing works
Incidences of Extrapyramidal Symptoms in Patients with Schizophrenia after Treatment with Long-Acting Injection (Depot) or Oral Formulations of Olanzapine
Hill, A. L., Sun, B., & McDonnell, D. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.hisu.020813 · Cited by 8 · see citing works
Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada
Lam, A., Williams, R., Chandrasena, R. D., Beauclair, L., & Luong, D. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s54740 · Cited by 8 · see citing works
Self-citation

Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry
Olivares, J. M., Peuskens, J., Pečeňák, J., Resseler, S., Jacobs, A., Akhras, K. S., & on behalf of the e-STAR study group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903149306 · Cited by 62 · see citing works
Self-citation
Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries
Peuskens, J., Olivares, J. M., Pečeňák, J., Tuma, I. S. M., de Weg, H. B., Eriksson, L., Resseler, S., Akhras, K. S., Jacobs, A., & on behalf of the e-STAR study group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903488670 · Cited by 64 · see citing works
Self-citation
Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada
Lam, A., Williams, R., Chandrasena, R. D., Beauclair, L., & Luong, D. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s54740 · Cited by 8 · see citing works
Self-citation
Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
Apiquián, R., Córdoba, R., & Louzã, M. R. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s15911 · Cited by 15 · see citing works
Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database
Lambert, T. J. R., Emmerson, B., Hustig, H., Resseler, S., Jacobs, A., & Butcher, B. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-25 · Cited by 15 · see citing works
Self-citation

Authors: Olivares, J. M., Rodriguez-Morales, A., Diels, J., Povey, M., Jacobs, A., Zhao, Z., & Lam, A.
Affiliations: University Hospital Complex Of Vigo (ES)
Janssen (Belgium) (BE)
Corresponding author: Olivares, J.M.
ORCID: Olivares, J.M.
Diels, J.
Povey, M.
Zhao, Z.
Lam, A.
Venue: European Psychiatry
Publisher: Cambridge University Press (CUP)
Published: 2009-06
Volume: 24
Issue: 5
Pages: 287-296
ISSN: 0924-9338 (ISSN-L)
1778-3585
DOI: 10.1016/j.eurpsy.2008.12.002
OpenAlex: W1969486406
Cited by: 141
References: 36
Citations by year: 2025: 1 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 5 · 2020: 7 · 2019: 3 · 2018: 4 · 2017: 8 · 2016: 10 · 2015: 19 · 2014: 9 · 2013: 28 · 2012: 17
FWCI: 8.43
Type: journal article
Language: en
Open access: closed
Licence: www.cambridge.org/core/terms (unspecified, 3972 d)
Locations: European Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Keywords: schizophrenia, long-acting injectable risperidone, oral antipsychotics, medication adherence, treatment retention, hospitalization, Clinical Global Impression Scale, olanzapine, long-term outcomes
MeSH terms: Olanzapine, Administration, Oral, Adult, Benzodiazepines, Delayed-Action Preparations, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Injections, Intramuscular, Long-Term Care, Male, Middle Aged, Patient Readmission, Prospective Studies, Psychiatric Status Rating Scales, Registries, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Risperidone, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks